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ABSTRACT
The traditional treatment of venous
thromboembolism (VTE) has been use of
heparin and vitamin K antagonists (VKA), and
although shown to be effective, they have
numerous limitations. New oral anticoagulants
(NOACs) including direct thrombin (factor IIa)
inhibitors (dabigatran) and selective factor Xa
inhibitors (rivaroxaban, apixaban and
edoxaban) have emerged as promising
alternatives with the potential to overcome
the limitations of traditional treatments.
Clinical trials have been performed with a
view to making significant changes to the
acute, long-term and extended treatment of
VTE. Data are now available on the efficacy and
safety, including bleeding rates, of the NOACs
in comparison with VKA in the acute treatment
and secondary prevention of VTE as well as in
comparison with placebo extended VTE
treatment. This review compares and contrasts
the design and results of the Phase III trials of
NOACs in VTE and discusses the implications of
the NOACs in terms of treatment strategies in
VTE patients.
Keywords: Clotting factor inhibitors; Low
molecular weight heparin; New oral
anticoagulants; Oral anticoagulant; Venous
thromboembolism
INTRODUCTION
Deep-vein thrombosis (DVT) and pulmonary
embolism (PE), collectively known as venous
thromboembolism (VTE), are a major
healthcare concern resulting in considerable
long-term morbidity and mortality. According
to estimates, VTE affects more than one million
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individuals each year across the EU and over
600,000 people each year in the USA [1, 2]. The
number of annual VTE-related deaths is also
considerable, approaching approximately
540,000 and 300,000 in the EU and USA,
respectively [1, 2]. In addition, the burden of
DVT frequently extends beyond the original
event because patients with symptomatic VTE
have a high risk of recurrence (including non-
fatal and fatal PE) that persists for many years.
For half a century, the standard of care for
most patients with VTE has been initial heparin,
overlapped and followed up with a vitamin K
antagonist (VKA) [3–5]. The effectiveness of this
regimen has been well described in the short-
term treatment of VTE, with the risks of
recurrent disease reduced by around 82%.
However, this regimen is complex to
implement in clinical practice [6–9]. Although
they are recommended in current guidelines for
the treatment of VTE [5, 10], traditional VTE
treatments have numerous limitations. For
example, unfractionated heparin (UFH), low
molecular weight heparin (LMWH) and
fondaparinux require parenteral
administration, while the oral VKAs have a
slow onset of action, require regular
international normalization ratio (INR)
monitoring and have numerous drug and food
interactions [3, 11, 12]. These limitations make
the management of patients with VTE difficult,
and they negatively affect patients’ quality of
life [13, 14]. Intensive research is continuing to
focus on new oral anticoagulant (NOAC)
agents, including three factor Xa inhibitors
(rivaroxaban, apixaban and edoxaban) and
one thrombin (factor IIa) inhibitor (dabigatran
etexilate), all of which have the potential to
overcome the limitations of traditional
therapies [15]. VKAs act non-specifically at
various steps in the coagulation cascade, while
the NOACs act directly on factor Xa or
thrombin and, unlike VKAs, they do not
require routine INR monitoring and have
minimal drug and food interactions [15].
Current VTE guidelines are generally vague
on the length of therapy, particularly extended
therapy beyond 3–6 months [5]. The prevention
and treatment of VTE must be tailored to an
individual patient’s needs, which primarily
depend on the risks of having a recurrent VTE
event or a bleed. With traditional treatments,
and also now with the emerging NOACs, these
two important potential outcomes need to be
carefully weighed against each other, and with
on-going assessment of other risks and benefits
when a decision is made on the duration of VTE
treatment (Table 1) [5, 16–19]. Recent studies
investigating the acute treatment, secondary
prevention and extended treatment of VTE with
NOACs, warfarin and aspirin have made many
clinicians reconsider the risks and benefits of
anticoagulant treatment. These investigations
Table 1 Risk factors for recurrence of VTE and bleeding











Increasing age Chronic renal or hepatic
disease
Proximal DVT Concomitant antiplatelet
therapy
Cancer Poor anticoagulant control




DVT deep-vein thrombosis, VTE venous
thromboembolism
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may result in an adjustment of the balancing of
bleeding risk and VTE recurrence, and therefore
of the recommendations for the duration of
therapy. This is because the NOACs dabigatran,
rivaroxaban, apixaban and edoxaban have
demonstrated non-inferior efficacy compared
with the standard of care either versus LMWH
and VKA (rivaroxaban and apixaban) or VKA
(dabigatran and edoxaban). Rivaroxaban,
apixaban and dabigatran were superior in
terms of efficacy to placebo in extended
therapy [20–27]. With regard to bleeding rates
during acute treatment of patients with VTE,
the results varied by the outcome measured,
however, both standard measurements,
described below, showed a trend to reduction
for all four NOACs. Patients who received
apixaban had significantly fewer major bleeds
than those with VKA and in patients with PE,
rivaroxaban was associated with a significantly
lower rate of major bleeding than VKA [18, 21].
Edoxaban, apixaban and dabigatran were
associated with significantly fewer of the
combined major or clinically relevant non-
major bleeding events than VKA, while
rivaroxaban showed no difference versus VKA
[17–19, 21–23]. During studies of extended
treatment of VTE, only dabigatran was
compared with VKA treatment and was
associated with significantly less major or
clinically relevant non-major bleeding [20].
As there is a very limited amount of long-
term clinical evidence with the NOACs versus
VKA treatment and limited post-marketing
surveillance with the NOACs, the safety of
these agents for long-term treatment in
clinical practice is currently unclear.
Clinical studies with the NOACs were
performed with a view to making significant
changes to the acute and extended treatment of
VTE. It is important to understand and compare
the methodology utilized in each of the studies,
to assess their limitations and put results with
the NOACs into perspective. This review will
compare and contrast the design and results of
the Phase III trials of NOACs in VTE and discuss
the implications of the NOACs in terms of
treatment strategies in VTE patients.
Studies were identified from a search of the
PubMed database (US National Library of
Medicine, Bethesda, USA) for each of the
NOACs, apixaban, dabigatran, edoxaban and
rivaroxaban with venous thromboembolism,
and Phase III clinical studies were identified
(Tables 1, 2).
The analyses in this article are based on
previously conducted studies, and no new
studies of human or animal subjects
performed by any of the authors are presented.
DESIGN AND LIMITATIONS
OF NOAC STUDIES IN VTE
A number of limitations have been observed in
the phase III clinical trials (Table 2). The studies
with dabigatran, rivaroxaban, apixaban and
edoxaban vary in terms of their individual
designs and patient characteristics (Tables 3,
4). All of the studies comparing a NOAC with
either LMWH and VKA, or VKA were non-
inferiority studies. In addition, all of the VTE
studies had exclusion criteria for patients with
severe renal impairment because they are all at
Table 2 Frequent limitations in clinical studies
Limitations in clinical trials
Too small
Too restricted in age (lack of young or elderly)
Too well, little comorbidity, milder disease, safer and
more compliant patients
Too short and follow-up limited
Too little information on drug interactions
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least partially excreted via the kidneys. Major
differences in design were seen in the use of
initial heparin therapy, open-label or double-
blind treatment, once-daily or twice-daily
dosing, dose adjustment during the study,
treatment duration and follow-up duration
(Tables 3, 4). The EINSTEIN-PE (NCT00440193)
and EINSTEIN-DVT (NCT00439777) studies that
compared rivaroxaban with heparin and VKA
were open-label, which contrast with the
double-blind studies that compared
dabigatran, apixaban and edoxaban with VKA
[20–26, 28]. Another substantial difference is
the use of a heparin lead in, which is the
recommended standard of care [5]. The RE-
COVER I (NCT00291330) and RE-COVER II
(NCT00680186) studies with dabigatran and
the Hokusai-VTE (NCT00986154) study with
edoxaban used a heparin lead in, but heparin
was not used in the VTE studies with
rivaroxaban and apixaban [20–23, 26–28].
Regarding dosing, a long-term once-daily
dosing regimen was used in the rivaroxaban
studies and a once-daily regimen was used
throughout the edoxaban studies, while a
twice-daily regimen was used in the dabigatran
and apixaban studies. Dose adjustment at
randomisation or maintenance-dose
adjustment during the course of the study did
not occur during the EINSTEIN, AMPLIFY
(NCT00643201), RE-COVER, RE-MEDY
(NCT00329238) or RE-SONATE
(NCT00558259) studies [20–25, 27]. However,
dose adjustment at randomisation and also at
any point during the study was performed in
the Hokusai-VTE study with edoxaban. In
addition, Hokusai-VTE was the only study to
assess all patients at the same time point
(12 months), regardless of treatment duration
(3–12 months) [26]. A large degree of variation
is seen in the size of the acute VTE studies. The
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Table 4 Comparison of design of placebo-controlled VTE extension studies with NOACs
EINSTEIN-Extension [21] AMPLIFY-Extension [20] RE-SONATE [24]
Identiﬁer NCT00439725 NCT00633893 NCT00558259
Release 2010 2012 2013
Indications Extended treatment in proximal
DVT or PE
Extended treatment in acute
proximal DVT or PE
Extended treatment in proximal
DVT or PE
NOAC Rivaroxaban Apixaban Dabigatran
Dosing
regimen
Rivaroxaban 15 mg BID
(3 weeks), then 20 mg QD
Apixaban 5 mg BID or Apixaban
2.5 mg BID
Dabigatran 150 mg BID
























Aged 18 and above, conﬁrmed
acute symptomatic PE or DVT,
previously treated with
rivaroxaban or VKA for 6 or
12 months and clinical
equipoise for continued
anticoagulation
Aged 18 and above, conﬁrmed
acute symptomatic DVT or PE,
previously treated with apixaban
or VKA for 6 to 12 months and
clinical equipoise for continued
anticoagulation
Aged 18 and above, conﬁrmed
acute symptomatic DVT or PE,
previously treated with VKA for





\30 ml/min excluded \25 ml/min excluded B30 ml/min excluded










Discouraged Permitted with caution Not indicated
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The two RE-COVER studies with dabigatran
were the smallest acute VTE trials, with
approximately 2,570 patients each [23, 27].
Patient Characteristics
The design of the VTE studies, characteristics of
patients randomized and the variation in study
design impose a number of limitations in
relation to the generalizability of the results
obtained to a clinical practice setting.
Mortality is an important indicator of level
of illness in any group of patients enrolled into
a clinical study. The rates reported in the acute
VTE studies are, therefore, of great interest to
fully understand the relevance of the studies in
clinical practice. The studies that had around
6 months of follow-up including the EINSTEIN
studies reported mortality rates slightly above
2% and the AMPLIFY and RE-COVER studies
reported rates slightly below 2% [21–23, 25, 27].
The study that followed all patients for
12 months, Hokusai-VTE, reported
approximately 3.2% total mortality [26].
However, the different lengths of follow-up
and the different analyses of the study
populations, with and without patients off
treatment, do not allow direct between-study
comparisons of mortality rates.
In addition to mortality, the range of
anatomical extent of PE at baseline also
provides an important insight into the
relevance of the studies in clinical practice.
Both the EINSTEIN-PE and Hokusai-VTE studies
used the same criteria to define anatomical
extent of PE, with extensive PE defined as
involvement of multiple lobes with 25% or
more of the entire vasculature. In EINSTEIN-PE,
extensive PE was present in approximately 24%
of patients and in Hokusai-VTE it was present in
approximately 45.8% of patients. The AMPLIFY
study used different criteria to define extensive
PE, which were at least two lobes with at least
50% of vasculature for each lobe, and
approximately 37.2% of patients had extensive
PE according to these criteria in AMPLIFY [22,
25, 26]. Despite the varying criteria utilized, the
highest reported proportion of patients with
extensive PE was in the Hokusai-VTE study [18,
21, 22].
Patient age is a key factor and it has
previously been found that the half-life and
exposure of the NOACs dabigatran, rivaroxaban
and apixaban are higher in the elderly [29].
Also, elderly patients are more likely to suffer
greater bleeding complications both with and
without anticoagulation [30]. Although no
upper-age limits were set with regard to
randomisation of patients, elderly and younger
patients were under-represented and mean ages
ranged from 54 to 58 years (Table 3). The
placebo group of the EINSTEIN-Extension
Table 4 continued





Low-dose single agent allowed Not indicated
Coagulation
disorder
Not indicated Excluded Excluded
BID twice daily, CrCl creatinine clearance, DVT deep-vein thrombosis, NOAC new oral anticoagulant, NSAID non-
steroidal anti-inﬂammatory drug, PE pulmonary embolism, QD once daily, VKA vitamin K antagonist, VTE venous
thromboembolism
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(NCT00439725) trial had the highest mean age
in any of the trials at 58.4 years [21]. With
regard to race and ethnicity, patients were
predominantly Caucasian in most of the
studies even though the trials were
multinational. For example, 94.8% of patients
in the RE-COVER study were Caucasian [23].
Although the larger Hokusai-VTE study had a
predominantly Caucasian study population
(approximately 70%), the study also had a
varied ethnic composition with 21% Asian and
around 3.5% Black or African–American
patients, and hence was the largest and most
internationally representative VTE study [26].
Renal function is also a key factor in
treatment with a NOAC and patients with
renal impairment were under-represented in
clinical trials. The AMPLIFY and AMPLIFY-
Extension (NCT00633893) trials excluded
patients with a creatinine clearance of \25 ml/
min [20]. In AMPLIFY, the apixaban arm had
64% of patients with a creatinine clearance
[80 ml/min and approximately 6% of patients
had a creatinine clearance \50 ml/min [25]. A
similar proportion was observed in the
AMPLIFY-Extension study, approximately 71%
of patients in the apixaban arm had a creatinine
clearance [80 ml/min and only 5–6% of
patients had a creatinine clearance \50 ml/
min [20]. The Hokusai-VTE trial also included
few patients with renal impairment, less than
7% of patients had a creatinine clearance of
C30 ml to \50 ml/min. Although patients with
a creatinine clearance \30 ml/min were
excluded from the EINSTEIN trials, some
patients with a lower creatinine clearance were
enrolled [21, 22]. Subsequent
pharmacodynamic modeling resulted in
rivaroxaban being utilized at an estimated
glomerular filtration rate as low as 15 ml/min.
Although no weight restrictions existed in the
trials, it is also clear that participants with a
body mass index (BMI) C35 kg/m2 were not
frequently randomized. The mean BMI of the
dabigatran group in the RE-COVER trial was
28.9 [standard deviation (SD) ± 5.7] kg/m2 [23].
In Hokusai-VTE, approximately 13% of patients
had a body weight B60 kg and 15% weighed
[100 kg [22]. The mean weight of the apixaban
2.5 mg group in the AMPLIFY-Extension trial
was 85.7 (SD ± 19.8) kg. In the AMPLIFY study,
approximately 72% of the apixaban group
weighed 60–100 kg and 19% weighed C100 kg
[25]. In the EINSTEIN studies, approximately
14% of patients had a body weight[100 kg [17,
18]. A BMI C30 kg/m2 was found in around 30%
of patients in the EINSTEIN, AMPLIFY and RE-
COVER studies, and in AMPLIFY and RE-COVER
around 12% had a BMI C35 kg/m2 [21–23, 25].
The proportion of obese patients is broadly
consistent with levels found in population
studies.
Overall, the limited inclusion of elderly
patients, patients with renal impairment, very
obese patients and patients from non-white
ethnic groups may reduce the generalizability
of the results of VTE studies in clinical
practice.
The VTE study publications also provide
limited information on drug interactions,
which may have been very useful information
for clinical practice. The AMPLIFY and
EINSTEIN trials excluded patients taking
strong cytochrome P-450 inhibitors/inducers,
which means that they should not be
recommended for patients who require these
agents [21, 22, 25, 26]. In addition, although
concomitant low-dose aspirin use was
permitted in all of the studies, only the
Hokusai-VTE study investigators reported any
analysis of the effect of aspirin on efficacy and
bleeding rates. These subgroup analyses did not
find any effect of concomitant aspirin on the
efficacy and safety of edoxaban [26].
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Heparin Lead In
There are other facets of trial design that are
important to consider when translating trial
evidence into clinical practice. The duration
and use of a parenteral heparin lead in prior to
commencing NOAC therapy varied across the
trials. In the RE-COVER trial the median length of
parenteral anticoagulation post-randomisation
was 6 days and in Hokusai-VTE the median
length was 7 days, therefore, there is currently
no evidence to support the immediate use of
initial dabigatran or edoxaban monotherapy in
VTE treatment [23, 26]. The EINSTEIN-PE and
EINSTEIN-DVT trials excluded patients who had
received more than 48 h of parenteral
anticoagulation and the AMPLIFY study also
excluded patients who received more than
1 day of LMWH therapy, or more than 36 h of
continuous intravenous heparin [21, 22, 25].
However, it is known that the rate of VTE
recurrence is highest during initial parenteral
therapy and during the transition to VKA in this
treatment strategy [31]. This raises the possibility
that recurrence rates could be higher than those
observed in the trials. Only few patients in the
clinical trials used rivaroxaban and apixaban as a
monotherapy because approximately 80–90%
received a pre-randomisation dose of parenteral
heparin. However, a subgroup analysis of
EINSTEIN did not confirm differences between
patients who only received rivaroxaban and
those who had initial parenteral therapy [21].
The optimal strategy for using or not using a
heparin lead in has not been determined in a
randomized trial and, therefore, this is an open
issue. In clinical practice some physicians may
prefer to use NOAC monotherapy for VTE
treatment in lower risk patients suitable for
outpatient therapy, while others may prefer a
heparin lead in, especially for sicker patients
requiring inpatient therapy.
Use of Blinding
Another major difference in trial design is the
use of open- or double-blinded methodology.
Double-blinded trials are traditionally viewed as
the ‘gold standard’ in design. Blinding protects
against detection and reporting bias arising from
patients and investigators knowing which
treatment is being received. However, blinding
results in the loss of information that may reflect
true differences in a randomized trial with
respect to the quality of life experienced with
different regimens. The EINSTEIN-DVT and
EINSTEIN-PE trials were open-label and,
therefore, a direct comparison of the effects of
rivaroxaban and VKA on quality of life could be
performed. A higher rate of recurrent VTE
episodes was suspected in the rivaroxaban arm
than in the VKA arm in the EINSTEIN-DVT trial,
indicating a possible diagnostic-suspicion bias
against rivaroxaban. However, the blinded
central adjudicating committee did not
confirm higher VTE recurrences in the
rivaroxaban arm [21]. Double-blinded trials are
complex in the context of anticoagulant
therapy. The AMPLIFY, Hokusai-VTE and RE-
COVER trials used double-dummy methodology
to maintain blinding and minimize bias. In
these studies, the arm receiving active NOAC
also received placebo warfarin together with
‘sham INR’ monitoring. In addition to making
patient recruitment harder, patient selection
bias may occur in double-dummy trials as
investigators may doubt the ability of elderly
or frail patients to follow complex instructions
[32]. In general, double-dummy trials also tend
to have higher discontinuation rates, as is seen
in the RE-COVER trial (15.2% discontinuation)
compared with the open-label EINSTEIN-PE
(11.5% discontinuation) and EINSTEIN-DVT
(12.8% discontinuation) trials. However, the
double-dummy Hokusai-VTE study had a
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discontinuation rate of 4.2%, which was the
lowest in any of the VTE studies. This may be
explained by the extremely low proportion of
patients who withdrew consent (\0.9%) or who
were lost to follow-up (\0.2%) in Hokusai-VTE
[26]. Double-dummy design may also bias
towards a higher time in therapeutic (TTR)
range, in relation to INR control, by selecting
more compliant patients [32]. The mean TTR
observed in clinical studies using a VKA to treat
VTE has been estimated at 60% [33]. Although
the methods of assessing TTR vary from trial to
trial, the RE-MEDY trial with dabigatran had the
highest mean TTR of 65% [24]. A selection-to-
continue bias present in the extended treatment
RE-MEDY trial may have also contributed to the
higher TTR achieved. The EINSTEIN-DVT open-
label trial with rivaroxaban had a lower TTR of
57% than the EINSTEIN-PE which had a TTR of
63%, indicating more stringent control in PE
patients compared with DVT patients. Clinical
trial results for TTR are higher than normally
seen in clinical practice. The mean TTR varies in
reported series, however, a very large study in
the United States demonstrated that in a real-
world population, less than 50% of warfarin
patients achieved INR values within the
therapeutic range [34]. Furthermore, adherence
is often poor, missed and extra doses are not
uncommon and subsequently INR is frequently
out of range [35]. It is important to consider that
missing doses of NOACs would also result in
patients’ anticoagulation becoming sub-
therapeutic. NOACs have a shorter half-life
than warfarin, and therefore a missed dose
may pose a greater short-term risk of VTE
recurrence [36].
Statistical Analyses and Sample Size
All of the trials comparing a NOAC with VKAs
were designed to assess for non-inferiority and
utilized intention-to-treat analyses, but it is
recommended to also perform a per-protocol
analysis because this strengthens an
equivalence finding if both analyses are in
agreement [37]. The evidence for non-
inferiority of NOACs may depend on the
quality of VKA treatment reflected by TTR. In
addition, premature discontinuation, small
sample size, lack of blinding and effects of
concomitant medication all may increase the
chance of finding non-inferiority when a true
difference exists [38]. The incentive to reduce
the impact of these factors is greater when a trial
aims to demonstrate superiority. The
importance of sample size was observed in the
non-inferiority RE-COVER trial, which may
have initially been too small as a low rate of
recurrent VTE was observed [23]. The replica RE-
COVER II study was then conducted to confirm
the findings of RE-COVER [27]. The VTE trial
with the largest study population was Hokusai-
VTE in 8,292 patients, which was more than
double the size of RE-COVER [22].
Treatment Duration
The duration of VTE treatment is a key issue for
every patient to balance the risk of recurrence
and bleeding effectively. It is important to
optimize treatment duration dependent on
patients’ characteristics. Although the risk of
VTE recurrence is highest within the initial
6 months, it does not return to normal after this
period and it is also of note that the optimal
duration of VTE treatment still remains unclear
in clinical guidelines [31]. Most of the acute VTE
trials with the NOACs did not have long follow-
up periods, and important information about
the recurrence rates of VTE upon cessation of
NOAC treatment compared with VKA was not
obtained. A more complete picture of the effect
of length of treatment could have been
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determined if all patients in the NOAC trials
were followed for the same length of time and
all events were collected over that time period.
The only exception was Hokusai-VTE, which
had a flexible treatment duration of
3–12 months and all patients were analyzed at
12 months [26]. In the double-blind, double-
dummy Hokusai-VTE trial, 40% of patients
completed 12 months of treatment,
approximately 62% had [6 months of therapy
and 26% had 3 to B6 months of therapy [26].
This suggests that in a patient population
comprised of large numbers of patients with
extensive PE (46%) and extensive DVT (42%),
the extent of disease does not determine length
of therapy. The investigators’ previous double-
dummy clinical trial experience and the flexible
treatment duration in Hokusai-VTE may have
been two of the reasons that very low levels of
patient discontinuation and withdrawal of
consent were observed, as compared with the
other VTE studies. Insights into the appropriate
duration of treatment for provoked,
unprovoked, limited and extensive PE and
DVT could be made from further analyses of
the Hokusai-VTE study, including recurrence
rates after cessation of treatment. In addition,
the extension trials with dabigatran,
rivaroxaban and apixaban add to the growing
evidence in support of continued
anticoagulation in certain clinical settings.
CLINICAL RESULTS FROM NOAC
STUDIES IN VTE
Acute Treatment and Secondary
Prevention Studies
Promising results have been obtained with the
NOAC agents dabigatran, rivaroxaban,
apixaban and edoxaban in acute VTE
treatment and secondary prevention studies
(Table 5). The RE-COVER trial compared
heparin/dabigatran 150 mg twice daily with
heparin/warfarin in the prevention of
recurrent or fatal VTE and found that heparin/
dabigatran was non-inferior to heparin/warfarin
(p\0.001 for non-inferiority) [23]. Dabigatran
was also associated with significantly fewer
major or clinically relevant non-major
bleeding, as well as any bleeding events
(Table 5) [23]. The replica RE-COVER II trial
confirmed that the efficacy of heparin/
dabigatran in acute VTE was non-inferior to
heparin/warfarin and dabigatran also had a
lower risk of bleeding [27]. Similar results have
been observed with rivaroxaban, which was
compared with standard enoxaparin/VKA
therapy in acute symptomatic proximal DVT
in EINSTEIN-DVT and in acute symptomatic PE
with or without symptomatic DVT in
EINSTEIN-PE [21, 22]. Both studies found
rivaroxaban was non-inferior compared with
enoxaparin/VKA in the prevention of
symptomatic, recurrent VTE. In both studies,
rivaroxaban was associated with comparable
levels of major or clinically relevant non-major
bleeding and in EINSTEIN-PE the rivaroxaban
group had significantly fewer major bleeding
events than standard therapy [21, 22]. The
AMPLIFY study demonstrated that apixaban
was non-inferior to conventional therapy with
enoxaparin followed by warfarin, in the
prevention of recurrent VTE or related death.
Apixaban treatment was also associated with a
significantly lower risk of major or clinically
relevant non-major bleeding than conventional
therapy [25]. The Hokusai-VTE study
demonstrated that edoxaban was non-inferior
to warfarin in the prevention of recurrent
symptomatic VTE and edoxaban was also
associated with significantly fewer major or
clinically relevant non-major bleeding events
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than warfarin at 12 months. Approximately
17.5% of the Hokusai-VTE study population
qualified for dose reduction from edoxaban
60 mg to 30 mg. Among the dose-adjusted
group, 22/733 (3.0%) edoxaban patients and
30/719 (4.2%) warfarin patients had recurrent
VTE events (HR 0.73; 95 % CI 0.42–1.26), which
correlated with results in the overall study
population [26].
Extended Secondary Prevention Studies
The duration of treatment is an uncertain issue
in VTE treatment because the benefit of
preventing VTE recurrence and risk of bleeding
must be balanced for each patient. Following on
from the acute VTE treatment studies,
continued long-term therapy with the NOACs
dabigatran, rivaroxaban and apixaban have
been performed and provided promising
results. The RE-MEDY study (Tables 3, 5)
compared dabigatran with warfarin in a 6- to
36-month extended treatment period after
3–12 months of initial VTE therapy [24].
Dabigatran showed non-inferior efficacy
compared with warfarin in the primary
outcome of symptomatic, recurrent VTE or
VTE-related death and significantly fewer
bleeding events and major or clinically
relevant non-major bleeds were observed with
dabigatran than warfarin [24]. However,
patients in the dabigatran group had a
significantly higher rate of acute coronary
syndrome events than those in the warfarin
group (p = 0.02) [20]. A similar observation was
made in patients with atrial fibrillation who
received dabigatran compared with warfarin
during the RE-LY trial [35].
Placebo-controlled extension studies have
also been performed with the NOACs to
investigate benefits compared with treatment
cessation (Tables 4, 6). The RE-SONATE study
compared dabigatran with placebo in a 6- to
18-month extension period that followed
6–18 months of initial VTE treatment [24]. RE-
SONATE showed that long-term treatment was
significantly more effective than placebo
(p\0.001) in prevention of symptomatic
recurrent VTE and related deaths. However,
dabigatran treatment was associated with a
significantly higher rate of any bleeding and
major or clinically relevant bleeding. In the
EINSTEIN-Extension study with a 6- or
12-month extension, rivaroxaban was
associated with significantly fewer
symptomatic, recurrent VTE events than
placebo (p\0.001) [21]. The rivaroxaban arm
had a significantly higher incidence of major or
clinically relevant non-major bleeding than
placebo (p\0.001), as well as comparable non-
fatal major bleeding to placebo. In the
12-month AMPLIFY-Extension study in
symptomatic DVT or PE patients [16], both of
the apixaban 5 mg and 2.5 mg doses were
superior to placebo in prevention of
symptomatic, recurrent VTE or death from any
cause (p\0.001 for both comparisons). The rate
of major bleeding was similar in the three
treatment groups at 0.5% (n = 4) with placebo,
0.2% (n = 2) with apixaban 5 mg and 0.1%
(n = 1) with apixaban 2.5 mg. Although the
placebo group had the highest rate of major
bleeds, no significant difference was observed
and such fluctuations are likely to occur by
chance. In addition, the rate of major or
clinically relevant non-major bleeding was
2.7% in the placebo group, 4.3% in the
apixaban 5 mg group and 3.2% in the
apixaban 2.5 mg group [16]. Based on these
bleeding data, some commenters have
speculated that the intermediate dose of
apixaban 2.5 mg may be most beneficial in
extended treatment. Taken together, the
placebo-controlled RE-SONATE, EINSTEIN-
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Table 6 Comparison of results of placebo-controlled VTE extension studies with NOACs
EINSTEIN-Extension [21] AMPLIFY-Extension [20] RE-SONATE [24]
Study population (%)
Unprovoked 73.7 91.7 Not indicated
Proximal DVT 62.0 65.4 64.9
PE 38.0 34.6 33.0
Previous VTE 16.1 12.7 Not indicated
Active Cancer 4.5 1.7 0.2
Anatomical extent of PE (%)*
Limited Not indicated Not indicated Not indicated
Intermediate Not indicated Not indicated Not indicated
Extensive Not indicated Not indicated Not indicated
Not assessable Not indicated Not indicated Not indicated
Study outcomes (NOAC vs. placebo)
Recurrent VTE
Absolute rate (%) 1.3 vs. 7.1 Apixaban 5 mg BID: 1.7 vs. 8.8;
ARR 7.0% [4.9–9.1]
p\0.001 for Sup





HR [95 % CI] 0.18 [0.09–0.39] 0.08 [0.02–0.25]
p value p\0.001 p\0.001 for Sup
Major bleeding
Absolute rate (%) 0.7 vs. 0 Apixaban 5 mg BID
0.1 vs. 0.5
RR 0.25 [0.03–2.24]




HR [95 % CI] HR not estimable HR not estimable
p value p = 0.11 p = 1.0
Major or CRNM bleeding
Absolute rate (%) 6.0 vs. 1.2 Apixaban 5 mg BID: 4.3 vs. 2.7
1.62 [0.96–2.73]




HR [95 % CI] 5.19 [2.3–11.7] 2.92 [1.52–5.60]
p value p\0.001 p = 0.001
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Extension and AMPLIFY-Extension studies
suggested that patients at clinical equipoise
between treatment continuation and cessation
may benefit from additional treatment. This
was demonstrated because the benefit of the
NOACs with an 80% reduction in preventing
recurrent venous thromboembolic events
exceeded the risk of major bleeding and
because the net clinical benefit was evident for
rivaroxaban and apixaban compared with
placebo [20, 21]. However, the optimal
duration of extended therapy with NOACs still
requires further clarification as only dabigatran
was compared with a VKA in RE-MEDY, the
other extension studies had a limited duration
of 12–18 months and patients were not
followed up after stopping anticoagulant
treatment in the EINSTEIN-Extension the
AMPLIFY-Extension studies [17, 20, 21].
Balancing VTE Recurrence and Bleeding
Rates
To help ascertain the benefit of the NOACs in
clinical practice, it is important to analyze
observed rates of VTE recurrence in relation to
bleeding (Figs. 1, 2). In the extended treatment
studies, rates of VTE recurrence were very low in
the anticoagulant groups (rivaroxaban,
apixaban and dabigatran) and were
significantly higher, around 10% in the
placebo groups. However, rates of clinically
relevant bleeding with rivaroxaban and
dabigatran were higher than placebo. The
lowest bleeding rate in this group of studies
was seen with apixaban. Although the extended
treatment RE-MEDY study found less bleeding
with dabigatran than warfarin, VTE recurrence
rates were slightly higher with dabigatran than
with warfarin. In the acute VTE studies,
bleeding rates with the NOACs were all less
than with VKA treatment. The AMPLIFY study
with apixaban, the EINSTEIN-DVT study with
rivaroxaban and Hokusai-VTE with edoxaban
suggested lower absolute rates of both VTE
recurrence and bleeding compared with VKA
treatment (Fig. 1).
DISCUSSION
VTE is a major burden on healthcare systems
around the world and traditional treatment
regimens with heparin and VKAs have a
number of significant limitations that have
limited their effectiveness in clinical practice
for several decades. An aging population will
most likely result in increase in the future
burden of VTE. The NOACs dabigatran,
rivaroxaban, apixaban and edoxaban have
demonstrated a potential to provide effective
Table 6 continued
EINSTEIN-Extension [21] AMPLIFY-Extension [20] RE-SONATE [24]
Minor bleeding Not indicated Not indicated Not indicated
Any bleeding Not indicated Not indicated 1.82 [1.23–2.68]
Total deaths Rivaroxaban n = 1 (0.2%)
Placebo n = 2 (0.3%)
Apixaban 2.5 mg BID: ARR -0.9%
Apixaban 5 mg BID: ARR -1.2%
HR not calculated
ARR absolute risk reduction, BID twice daily, CI conﬁdence interval, CRNM clinically relevant non-major, DVT deep-vein
thrombosis, HR hazard ratio, NOAC new oral anticoagulant, PE pulmonary embolism, RR relative risk, Sup superiority,
VTE venous thromboembolism
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alternative treatment in VTE patients. However,
clinical studies with the NOACs had a number
of limitations relating to the patients enrolled
and study designs. All of the studies enrolled
mostly Caucasian patients, had a very low
proportion of both young and elderly patients,
had few very obese patients, as well as patients
with few comorbidities and a relatively low risk
of VTE recurrence. In addition, very little
information on possible drug interactions has
been published. Most of the acute VTE studies
had short, limited follow-up periods that have
meant limited information on the appropriate
duration of VTE treatment was obtained. The
Hokusai-VTE study of edoxaban is the most
recent study and aimed to address some
weaknesses of previous trial designs. The study
was large, had a flexible treatment duration
which is more in line with clinical practice and
had a longer follow-up with all patients
analyzed at 12 months to aid treatment
duration comparisons. Dose adjustments were
allowed throughout the study as patient
characteristics and concomitant treatments
may change at any point in clinical practice
[26]. In addition, central tracking of INR for
each participating center and feedback to the
investigators were also undertaken to ensure
that a high TTR was achieved in the warfarin
group [26].
Fig. 1 VTE recurrence and rates of major or CRNM
bleeding in VTE studies that compared NOACs with
either LMWH and VKAs or VKAs. CI conﬁdence interval,
CRNM clinically relevant non-major. DVT deep-vein
thrombosis, HR hazard ratio, LMWH low molecular
weight heparin, NOAC new oral anticoagulant, VKA
vitamin K antagonist, VTE venous thromboembolism
[21–27]
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In conclusion, all NOACs have shown
similar efficacy to the standard of care:
heparins and VKA, they have also shown a
better safety profile than standard of care with
respect to the important outcome of bleeding.
The NOACs have their ‘‘pros and cons’’ with
respect to each other, some are once daily,
others are twice daily, and some require the use
of a parenteral heparin lead in, others do not.
The generalizability of results, the
characterization of the patients treated, the
extent of disease, the flexibility of dosing, and
the evidence for extended therapy also vary
between the studies. All these factors will need
to be considered when deciding which of the
NOACs to use in individual patients.
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